Skip to main content

Table 1 Basic molecular and clinicopathological characteristics of the study series

From: Identification of subgroup-specific miRNA patterns by epigenetic profiling of sporadic and Lynch syndrome-associated colorectal and endometrial carcinoma

 

Finnish CRC

Australian CRC

Finnish EC

 

Sporadic MSS

Sporadic MSI

Lynch

Sporadic MSS

Sporadic MSI

Lynch

Total number of tumors

47

40

28

52

38

36

Gender

      

Female

27

27

12

25

20

36

Male

20

13

16

27

18

-

Mean age of diagnosis (years)

69.9

72.8

43.6

67.6

67.1

50.2

Germline mutation present in MMR genes (total)

N/A

N/A

28

N/A

N/A

36

MLH1

  

28

  

30

MSH2

  

0

  

3

MSH6

  

0

  

3

MMR statusa

      

Deficient

0

40

28

0

38

36

Proficient

47

0

0

52

0

0

Tumor grade

      

1

13/21

5/14

5/16

1/52

0/36

14/29

2

5/21

6/14

6/16

46/52

24/36

9/29

3

3/21

3/14

5/16

5/52

12/36

6/29

Tumor stage (Dukes/WHO/FIGO)b

      

A/I/I

7/46

2/37

5/19

8/52

3/38

12/22

B/II/II

16/46

24/37

10/19

24/52

20/38

7/22

C/III/III

16/46

8/37

4/19

17/52

13/38

1/22

D/IV/IV

7/46

3/37

0/19

3/52

2/38

3/22

Location of CRCc

      

Proximal

20/44

34/39

22/27

20/52

27/38

-

Distal

24/44

5/39

5/27

32/52

11/38

-

  1. N/A, not applicable. aBased on microsatellite instability and immunohistochemical staining; baccording to the Dukes (A-D), World Health Organization (WHO) (I-IV), and International Federation of Gynecology and Obstetrics (FIGO) (I-IV) staging for CRC and EC, respectively. The denominator indicates the number of tumors for which data were available. cPrior to the splenic flexure for ‘proximal’ and distal to the splenic flexure for ‘distal’ (the denominator indicates the number of tumors with data available).